Hillevax Inc (HLVX NASDAQ) stock market data APIs
$2.0338
-0.04(-2%)
as of July 1, 2025
Try our APIs with
free plan!
Hillevax Inc Financial Data Overview
Price chart is built with
Anychart
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Prev. Close
2.0338
Open
1.9945
High
2.1027
Low
1.9945
52 wk Range
1.34-14.43
Market Cap
99 700 K
Shares Outstanding
50 101 K
EPS
-0.12
Beta
0.735
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hillevax Inc data using free add-ons & libraries
Get Hillevax Inc Fundamental Data
Hillevax Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -78 421 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.365
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hillevax Inc News
New
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates in adult...
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adu...
10 Buy-Rated Stocks with Latest Insider Purchases
In this article, we will take a detailed look at the 10 Buy-Rated Stocks with Latest Insider Purchases. For a quick overview of such stocks, read our article5 Buy-Rated Stocks with Latest Insider Pur...
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
